230 related articles for article (PubMed ID: 25145677)
1. Glucose availability and glycolytic metabolism dictate glycosphingolipid levels.
Stathem M; Marimuthu S; O'Neal J; Rathmell JC; Chesney JA; Beverly LJ; Siskind LJ
J Cell Biochem; 2015 Jan; 116(1):67-80. PubMed ID: 25145677
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic potential of targeting ceramide/glucosylceramide pathway in cancer.
Kartal Yandım M; Apohan E; Baran Y
Cancer Chemother Pharmacol; 2013 Jan; 71(1):13-20. PubMed ID: 23073611
[TBL] [Abstract][Full Text] [Related]
3. Tyrosine-phosphorylation and activation of glucosylceramide synthase by v-Src: Its role in survival of HeLa cells against ceramide.
Honda T; Motoyoshi K; Kasahara J; Yamagata K; Takahashi H; Nakamura H; Murayama T
Biochim Biophys Acta Mol Cell Biol Lipids; 2021 Jan; 1866(1):158817. PubMed ID: 32980536
[TBL] [Abstract][Full Text] [Related]
4. Regulation of sphingolipid and glycosphingolipid metabolism in extrahepatic tissues by endotoxin.
Memon RA; Holleran WM; Uchida Y; Moser AH; Grunfeld C; Feingold KR
J Lipid Res; 2001 Mar; 42(3):452-9. PubMed ID: 11254758
[TBL] [Abstract][Full Text] [Related]
5. Diabetes alters sphingolipid metabolism in the retina: a potential mechanism of cell death in diabetic retinopathy.
Fox TE; Han X; Kelly S; Merrill AH; Martin RE; Anderson RE; Gardner TW; Kester M
Diabetes; 2006 Dec; 55(12):3573-80. PubMed ID: 17130506
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of ceramide metabolism sensitizes human leukemia cells to inhibition of BCL2-like proteins.
Casson L; Howell L; Mathews LA; Ferrer M; Southall N; Guha R; Keller JM; Thomas C; Siskind LJ; Beverly LJ
PLoS One; 2013; 8(1):e54525. PubMed ID: 23342165
[TBL] [Abstract][Full Text] [Related]
7. Glucosylceramide synthase and glycosphingolipid synthesis.
Ichikawa S; Hirabayashi Y
Trends Cell Biol; 1998 May; 8(5):198-202. PubMed ID: 9695839
[TBL] [Abstract][Full Text] [Related]
8. An overview of sphingolipid metabolism: from synthesis to breakdown.
Gault CR; Obeid LM; Hannun YA
Adv Exp Med Biol; 2010; 688():1-23. PubMed ID: 20919643
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of glycosphingolipid biosynthesis reverts multidrug resistance by differentially modulating ABC transporters in chronic myeloid leukemias.
Salustiano EJ; da Costa KM; Freire-de-Lima L; Mendonça-Previato L; Previato JO
J Biol Chem; 2020 May; 295(19):6457-6471. PubMed ID: 32229586
[TBL] [Abstract][Full Text] [Related]
10. A role for ceramide glycosylation in resistance to oxaliplatin in colorectal cancer.
Madigan JP; Robey RW; Poprawski JE; Huang H; Clarke CJ; Gottesman MM; Cabot MC; Rosenberg DW
Exp Cell Res; 2020 Mar; 388(2):111860. PubMed ID: 31972222
[TBL] [Abstract][Full Text] [Related]
11. Ceramide glycosylation catalyzed by glucosylceramide synthase and cancer drug resistance.
Liu YY; Hill RA; Li YT
Adv Cancer Res; 2013; 117():59-89. PubMed ID: 23290777
[TBL] [Abstract][Full Text] [Related]
12. Targeting glucosylceramide synthase synergizes with C6-ceramide nanoliposomes to induce apoptosis in natural killer cell leukemia.
Watters RJ; Fox TE; Tan SF; Shanmugavelandy S; Choby JE; Broeg K; Liao J; Kester M; Cabot MC; Loughran TP; Liu X
Leuk Lymphoma; 2013 Jun; 54(6):1288-96. PubMed ID: 23181473
[TBL] [Abstract][Full Text] [Related]
13. Role of Glucosylceramide in Lung Endothelial Cell Fate and Emphysema.
Koike K; Berdyshev EV; Mikosz AM; Bronova IA; Bronoff AS; Jung JP; Beatman EL; Ni K; Cao D; Scruggs AK; Serban KA; Petrache I
Am J Respir Crit Care Med; 2019 Nov; 200(9):1113-1125. PubMed ID: 31265321
[No Abstract] [Full Text] [Related]
14. Role of Intracellular Lipid Logistics in the Preferential Usage of Very Long Chain-Ceramides in Glucosylceramide.
Yamaji T; Horie A; Tachida Y; Sakuma C; Suzuki Y; Kushi Y; Hanada K
Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27775668
[TBL] [Abstract][Full Text] [Related]
15. Regulation of glycosphingolipid metabolism in liver during the acute phase response.
Memon RA; Holleran WM; Uchida Y; Moser AH; Ichikawa S; Hirabayashi Y; Grunfeld C; Feingold KR
J Biol Chem; 1999 Jul; 274(28):19707-13. PubMed ID: 10391911
[TBL] [Abstract][Full Text] [Related]
16. Complex formation of sphingomyelin synthase 1 with glucosylceramide synthase increases sphingomyelin and decreases glucosylceramide levels.
Hayashi Y; Nemoto-Sasaki Y; Matsumoto N; Hama K; Tanikawa T; Oka S; Saeki T; Kumasaka T; Koizumi T; Arai S; Wada I; Yokoyama K; Sugiura T; Yamashita A
J Biol Chem; 2018 Nov; 293(45):17505-17522. PubMed ID: 30242129
[TBL] [Abstract][Full Text] [Related]
17. A novel mechanism of dasatinib-induced apoptosis in chronic myeloid leukemia; ceramide synthase and ceramide clearance genes.
Gencer EB; Ural AU; Avcu F; Baran Y
Ann Hematol; 2011 Nov; 90(11):1265-75. PubMed ID: 21455605
[TBL] [Abstract][Full Text] [Related]
18. Amyotrophic lateral sclerosis and denervation alter sphingolipids and up-regulate glucosylceramide synthase.
Henriques A; Croixmarie V; Priestman DA; Rosenbohm A; Dirrig-Grosch S; D'Ambra E; Huebecker M; Hussain G; Boursier-Neyret C; Echaniz-Laguna A; Ludolph AC; Platt FM; Walther B; Spedding M; Loeffler JP; Gonzalez De Aguilar JL
Hum Mol Genet; 2015 Dec; 24(25):7390-405. PubMed ID: 26483191
[TBL] [Abstract][Full Text] [Related]
19. Targeting Glycosphingolipid Metabolism to Treat Kidney Disease.
Shayman JA
Nephron; 2016; 134(1):37-42. PubMed ID: 26954668
[TBL] [Abstract][Full Text] [Related]
20. Glucosylceramide synthase inhibitors differentially affect expression of glycosphingolipids.
Alam S; Fedier A; Kohler RS; Jacob F
Glycobiology; 2015 Apr; 25(4):351-6. PubMed ID: 25715344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
